Breaks Categories: News

WednesdayFeb 07, 2024 1:50 pm

NetworkNewsBreaks – Prospera Energy Inc. (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) Announces Plan for Transitioning to Profitability in 2024

Prospera (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B) today issued a corporate update summarizing its restructuring since the first quarter of 2021, where the company has methodically executed the planned development phases and attained drilling results exceeding expectations and substantiating technical and economical applications. Prospera recapped results of its 2023 drilling program and, based on the successful results, the company is positioned to increase production primarily in medium light oil and continue the horizontal transformation to capture the substantial remaining heavy oil reserves. The horizontals enable the company to reduce environmental footprint, operating expense and asset retirement liability while appreciating production.…

Continue Reading

TuesdayFeb 06, 2024 3:19 pm

NetworkNewsBreaks — Toggle3D.ai (CSE: TGGL) (OTC: TGGLF) (FSE: Q0C) ‘Game-Changing’ 3D Modeling Solution Increases Productivity, Delivers Tangible Benefits

Toggle3D.ai (CSE: TGGL) (OTC: TGGLF) (FSE: Q0C), the all-in-one 3D modeling solution harnessing the power of generative artificial intelligence (“AI”) to convert CAD files, apply stunning 4K texturing and seamlessly publish superior 4K 3D models, is committed to redefining the 3D texturing landscape with its unparalleled speed and user-friendly interface. According to a recent release, the company is using Toggle3D to texture 3D models for Amazon as well as other customers; the announcement noted that its platform is increasing artists' productivity speed by 100% and users are seeing tangible benefits by reducing the time and cost of 3D model production. A…

Continue Reading

TuesdayFeb 06, 2024 3:13 pm

NetworkNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for a patent application related to the use of Lomecel-B(TM) in Aging-related Frailty sufferers receiving vaccines for conditions such as COVID-19 and influenza. “In our view, the notice of patent allowance further bolsters the Lomecel-B(TM) intellectual property (‘IP’) estate and may serve as a life-cycle management (‘LCM’) tool should additional evidence support the agent’s value…

Continue Reading

TuesdayFeb 06, 2024 3:05 pm

NetworkNewsBreaks – ARway.ai (CSE: ARWY) (OTC: ARWYF) (FSE: E65) Announces Game-Changing Launch, Early Access for ARwayKit SDK

Arway.ai (CSE: ARWY) (OTC: ARWYF) (FSE: E65) is an AI-powered augmented reality experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision. Arway.ai has announced the launch of its compatibility with Apple Inc.’s (NASDAQ: AAPL) Vision Pro alongside the revolutionary headset’s recent release. In addition, the company is now accepting submissions for its early access list for the ARwayKit SDK for the Apple Vision Pro. “The long awaited, highly anticipated Apple Vision Pro AR glasses are FINALLY here! We have been waiting for this moment for years and we knew eventually…

Continue Reading

TuesdayFeb 06, 2024 2:58 pm

NetworkNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Reports on Status of Initiatives, Financing

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, has released a report on recent company achievements and new initiatives as well as the completion of financing. The report noted a visit from the Honorable Lawrence MacAulay, Canada’s federal minister of agriculture, and two local members of parliament, the Honorable Bardish Chagger and MP Tim Louis; the trio visited FuelPositive’s Northland facility and engaged directly with FuelPositive’s team. The report also noted the following key items: the company remains on track to deliver its first commercial system in early spring…

Continue Reading

TuesdayFeb 06, 2024 2:39 pm

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Bollinger’s Receipt of IRS Approval for $40K Commercial EV Tax Credit

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that Bollinger Motors (“Bollinger”) has received IRS approval as a “qualified manufacturer” for clean vehicle credits under the Inflation Reduction Act of 2022 (the “IRA”). According to the announcement, the designation enables the Bollinger B4 chassis cab to qualify for the IRA’s new credit for qualified commercial clean vehicles, providing eligible purchasers a tax credit of up to $40,000 per vehicle. “Bollinger Motors is poised for growth and we’re ready to help electrify America’s fleets,” said Robert Bollinger, founder and CEO of Bollinger Motors. “These tax credits are…

Continue Reading

TuesdayFeb 06, 2024 2:23 pm

NetworkNewsBreaks — Paris Blockchain Week Hosts Press Event to Provide Sneak Peek of April’s Main Event

Paris Blockchain Week (“PBW”) hosted a press event in London last month in anticipation of April’s planned Paris Blockchain Week. Held Jan. 24, the press event was titled “Paris Blockchain Week Presents: A Taste of 2024 with Our Press Community.” The event was designed to give the media a peak at the planned agenda for the Upcoming blockchain week, including the cutting-edge discussions, industry leaders and innovative projects. The main Paris Blockchain Week event is scheduled for April 9–11, 2024. During the press event, three panels were held, discussing key topics in the ever-evolving blockchain and Web3 landscape, including the…

Continue Reading

TuesdayFeb 06, 2024 12:41 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD Pharma was awarded an additional $5,000 in costs by the Court of Appeal in respect to Dr. Raza Bokhari’s failed motion for leave to appeal. The judgment confirmed arbitration awards in which the arbitrator dismissed…

Continue Reading

TuesdayFeb 06, 2024 12:28 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb. 26, will include an overview of the company's gene therapies for cancer and diabetes; Confer will also be available for in-person, one-on-one meetings with investors through the conference platform. To view the full press release,…

Continue Reading

TuesdayFeb 06, 2024 12:12 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease and multiple sclerosis (“MS”). Etherington and Darling discussed the trial, which involved gathering almost three years of research and information from participants with stable relapsing MS. Darling explained…

Continue Reading